Welcome to Bayside Health | Alfred. More information about Bayside Health can be found at baysidehealth.org.au

Contact About Find a doctor Careers The Alfred Foundation For staff

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials

Data source: Bayside Health Alfred Powertrials list of active trials
Last updated: 3 September 2026

Clear filter

682 clinical trials found

Clinical trials

NVG-2089-201

A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants with Chronic Inflammatory Demyelinating Polyneuropathy [CIDP]

The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with CIDP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 is designed to potentially help the immune system by attaching (binding) to certain receptors in the body and activating them, which helps reduce inflammation and supports how the immune system works.

Currently recruiting

Ocean-Lpa

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein[a] (NCT05581303)

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).

Currently recruiting

OCEANIC AF

A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke (NCT05643573)

No longer recruiting

OCEANIC-STROKE

A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA (NCT05686070)

Currently recruiting

Odyssey Study

A Phase 2a, Two-Part, Open-Label and Randomized Study to Evaluate the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Patients with Moderately to Severely Active Ulcerative Colitis (NCT06850727)

The purpose of this study is to evaluate the clinical efficacy and safety of OD-07656 in participants with moderately to severely active ulcerative colitis (UC). In addition, the study will evaluate the potential of OD-07656 to enhance the therapeutic benefit of vedolizumab when given after OD-07656.

Currently recruiting

Olympia-1

A Phase 3, open-label, randomized study to compare the efficacy and safety of Odronextamab [REGN1979], an Anti-CD20 X Anti-CD3 bispecific antibody, versus investigators choice in previously untreated participants with Follicular Lymphoma. (NCT06091254)

Currently recruiting

OM336-SAI-1002

An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants with Active Sjogren’s Disease, Idiopathic Inflammatory Myopathy, or Pemphigus (NCT07229144)

This is an early-stage (Phase 1b) study to test the safety and tolerability of a study drug called OM336 in people with pemphigus that has not responded well to standard treatments. OM336 is administered subcutaneously in ascending dose cohorts. Eligible participants will receive four injections of the study drug over a month. After this period, all participants will continue on the study and be monitored for up to 48 weeks. What is involved? A screening period of up to 28 days to check eligibility, A 4-week treatment period where participants will receive the study drug, A follow-up period (with regular visits for health checks, blood tests and study assessments) of up to 48 weeks after the last dose of study drug.

Currently recruiting

OPTIMA

Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis (ISRCTN42400492)

No longer recruiting

ORCHID

A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps (ORCHID). (NCT04157335)

No longer recruiting

ORIGIN-1

ORganoId GuIded N-of-1 (ORIGIN-1) trial (ACTRN12623001136695)

Currently recruiting

PACE AUGMENT-AF

PACEmaker AUGMENTed AF ablation in participants with AF and sinus node disease – the PACE AUGMENT-AF Study (ACTRN12625000546459)

This study evaluates whether increased atrial pacing rate decreases AF recurrence and burden for patients with AF and sinus node dysfunction undergoing AF ablation.

Currently recruiting

PACIFICA

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/µL) (NCT03165734)

Currently recruiting

PC_ASP_006

A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis (NCT05238116)

Currently recruiting

PEPSTEP

Perampanel for the prevention of post-stroke epilepsy: a pilot phase II randomised controlled trial (ACTRN12618001984280)

Currently recruiting

PERFORM-CPR

Personalised Exercise Rehabilitation FOR people with multimorbidity (ACTRN12624001191583)

Many people in Australia are living with multiple long-term health conditions such as heart and lung disease, diabetes, arthritis, stroke, depression, and cancer. Exercise-based rehabilitation may help people with chronic conditions improve their physical function, symptoms and quality of life and help them spend less time in the hospital. However, until now there have been few exercise options for people living with multiple long-term health conditions. We are now conducting a study to see if a personalised rehabilitation program (PERFORM trial), which includes exercises and education sessions, can improve wellbeing and physical function better than usual care in people with multiple long-term health conditions.

Currently recruiting

Perseus

A Phase 3 Study Comparing Daratumumab, VELCADE [bortezomib], Lenalidomide, and Dexamethasone [D-VRd] vs VELCADE, Lenalidomide, and Dexamethasone [VRd] in Subjects with Previously Untreated Multiple Myeloma who are Eligible for High-dose Therapy. (NCT03710603)

No longer recruiting

PERSONAL

PERsonalised Selection Of medication for Newly diagnosed Adult epiLepsy (ACTRN12623000209695)

Currently recruiting

PESTO

A Prospective multicentre, phase 2b randomised controlled double-blind trial, to determine the safety and efficacy of perispinal etanercept on quality of life at 28 days post treatment. (ACTRN12620001011976)

Currently recruiting

PETRANHA

A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Patients with Metastatic Prostate Cancer (PETRANHA) (NCT05367440)